home / stock / skye / skye news

SKYE News and Press, Skye Bioscience Inc.

Stock Information
Company Name: Skye Bioscience Inc.
Stock Symbol: SKYE
Market: NASDAQ
Website: skyebioscience.com
Menu
Get SKYE Alerts

News, Short Squeeze, Breakout and More Instantly...
SKYE - Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing...
SKYE - UPDATE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or th...

SKYE - Skye Bioscience GAAP EPS of -$0.32

2026-05-11 16:04:48 ET More on Skye Bioscience Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript Skye Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new ...

SKYE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

CBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 Engaged Lilly Catalyze360 to provide strategic guidance on nimacimab TPP and Phase 2b trial design SAN DIEG...
SKYE - Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in B...

SKYE - Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, has treated the first patient in its Part C expansion st...

SKYE - US Companies Moving the Markets, Morning edition
Wed, Mar 11, 2026 as of 10.00 am ET

A look at the top 10 most actives in the United States KALA BIO Inc. (KALA) rose 55.8% to $0.458 on volume of 156,417,479 shares Scienture Holdings Inc. (SCNX) rose 45.7% to $0.5661 on volume of 84,046,263 shares SCWorx Corp. (WORX) rose 19.8% to $0.1517 on volume of 65,614,736 shares Sig...
SKYE - Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy

2026-03-10 21:01:15 ET More on Skye Bioscience Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript Skye Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Skye Bioscience Historical earnings data f...

SKYE - Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

2026-03-10 21:00:16 ET Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call March 10, 2026 4:30 PM EDT Company Participants Punit Dhillon - President, CEO, Principal Accounting Officer & Director Christopher Twitty - Chief Scientific Officer Tu Diep - Chief Opera...

SKYE - Skye Bioscience GAAP EPS of -$0.36 misses by $0.06

2026-03-10 16:04:02 ET More on Skye Bioscience Seeking Alpha’s Quant Rating on Skye Bioscience Historical earnings data for Skye Bioscience Financial information for Skye Bioscience Read the full article on Seeking Alpha For further details see...
Next 10